Detalles de la búsqueda
1.
Plasma Globotriaosylsphingosine and α-Galactosidase A Activity as a Combined Screening Biomarker for Fabry Disease in a Large Japanese Cohort.
Curr Issues Mol Biol
; 43(1): 389-404, 2021 Jun 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-34205365
2.
Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.
Genet Med
; 21(1): 44-52, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29543226
3.
Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.
Genet Med
; 21(8): 1900, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-30209272
4.
Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.
Genet Med
; 21(2): 512-515, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30190610
5.
Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.
Genet Med
; 21(5): 1263, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30728527
6.
Medullary thick ascending limb impairment in the GlatmTg(CAG-A4GALT) Fabry model mice.
FASEB J
; 32(8): 4544-4559, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29553830
7.
Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a mouse model of classic Fabry disease.
Mol Genet Metab Rep
; 34: 100952, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36624895
8.
Low bone mineral density due to secondary hyperparathyroidism in the GlatmTg(CAG-A4GALT) mouse model of Fabry disease.
FASEB Bioadv
; 2(6): 365-381, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32617522
Resultados
1 -
8
de 8
1
Próxima >
>>